Possibility of brigatinib ‐based therapy, or chemotherapy plus anti‐angiogenic treatment after resistance of osimertinib harboring EGFR T790M‐cis‐C797S mutations in lung adenocarcinoma patients

ConclusionBrigatinib-based therapy and chemotherapy plus anti-angiogenics could be considered beyond progression from osimertinib therapy. For patients harboringEGFR exon 19 deletion/T790M/cis-C797S mutation, the clinical efficacy was superior to patients harboringEGFR exon 21 p.L858R/T790M/cis-C797S mutation.

Source: Cancer Medicine - October 6, 2021 Category: Cancer & Oncology Authors: Yaning Yang, Haiyan Xu, Li Ma, Lu Yang, Guangjian Yang, Shuyang Zhang, Xin Ai, Shucai Zhang, Yan Wang Tags: RESEARCH ARTICLE Source Type: research